$6.14 6.6%
BMEA Stock Price vs. AI Score
Data gathered: December 12

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Biomea Fusion (BMEA)

Analysis generated June 22, 2024. Powered by Chat GPT.

Biomea Fusion is a cutting-edge biopharmaceutical company dedicated to the discovery and development of novel small-molecule covalent medicines. The company's innovative platform is designed to treat various diseases, emphasizing oncology and metabolic disorders. Biomea Fusion's commitment to research and development positions them as a unique player in the biopharmaceutical sector, leveraging next-generation covalent bonding techniques to create groundbreaking treatments.

Read full AI stock Analysis

Stock Alerts - Biomea Fusion (BMEA)

company logo Biomea Fusion | December 11
Price is up by 8.7% in the last 24h.
company logo Biomea Fusion | December 10
Twitter followers are down by 5.4% in the last 24h.
company logo Biomea Fusion | December 9
Price is down by -5.3% in the last 24h.
company logo Biomea Fusion | December 9
Twitter followers are down by 5.5% in the last 24h.

About Biomea Fusion

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases.


Biomea Fusion
Price $6.14
Target Price Sign up
Volume 889,170
Market Cap $210M
Year Range $4.14 - $13.28
Dividend Yield 0%
Analyst Rating 82% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '2406.8M-6.8M-33M-34M-0.910
Q2 '2407.1M-7.1M-37M-38M-1.030
Q1 '2407.3M-7.3M-39M-41M-1.090
Q4 '236.1M6.5M-6.5M-35M-36M-0.980
Q3 '2305.8M-5.8M-28M-31M-0.800

Insider Transactions View All

Hitchcock Michael J.M. filed to buy 15,000 shares at $10.1.
October 1 '24
Valle Franco filed to buy 42,500 shares at $4.4.
June 12 '24
A2A Pharmaceuticals, Inc. filed to sell 3,500,000 shares at $34.6.
June 2 '23
A2A Pharmaceuticals, Inc. filed to sell 3,550,000 shares at $33.8.
June 2 '23
A2A Pharmaceuticals, Inc. filed to sell 3,625,000 shares at $33.8.
May 17 '23

What is the Market Cap of Biomea Fusion?

The Market Cap of Biomea Fusion is $210M.

What is the current stock price of Biomea Fusion?

Currently, the price of one share of Biomea Fusion stock is $6.14.

How can I analyze the BMEA stock price chart for investment decisions?

The BMEA stock price chart above provides a comprehensive visual representation of Biomea Fusion's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Biomea Fusion shares. Our platform offers an up-to-date BMEA stock price chart, along with technical data analysis and alternative data insights.

Does BMEA offer dividends to its shareholders?

As of our latest update, Biomea Fusion (BMEA) does not offer dividends to its shareholders. Investors interested in Biomea Fusion should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Biomea Fusion?

Some of the similar stocks of Biomea Fusion are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.